ClinicalTrials.gg
TerminatedNCT00435877Updated Dec 17, 2019

Procurement of Tissue Samples for Cell Cultures and Analyses

An observational study in Bone Regeneration, Fracture Healing and Cell Culture Techniques, sponsored by National Institute of Dental and Craniofacial Research (NIDCR). Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-17.

Sponsored by National Institute of Dental and Craniofacial Research (NIDCR) · Observational

Study type
Observational
Time perspective
Prospective
Enrollment
2
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study will determine if bone marrow stromal cells can be used as a graft for regeneration of bony defects. These cells have the ability to form new bone and to support the formation of blood. Stromal cells have been identified in other tissues, such as the dermis (underside of skin), spleen, thymus and fat, but it is not known whether these cells can make bone and support blood formation as well as bone marrow stromal cells.

Patients undergoing surgery at Suburban Hospital in Bethesda, Maryland, in which some of the bone, dermis, spleen, thymus or fat tissue is removed may be eligible for this study.

For this study, a small piece of the tissue that is removed during surgery for examination by a pathologist will be used for research. Stromal cells from the specimen will be collected and grown in the laboratory. The genes and proteins in the different cell types will be compared, and the ability of stromal cells from the different tissues to make bone and to support the formation of blood will be studied.

Read the detailed description

Background: It is now apparent that virtually every human post-natal tissue contains some type of stem/progenitor cell population that is responsible for tissue turnover and repair. Our previous studies have identified a subset of human bone marrow stromal cells (BMSCs) that is multi-potent and able to regenerate bone, cartilage, myelosupportive stroma and adipocytes, whereas stromal cells derived from human spleen (SpSCs) and thymus (TSCs) only form myelosupportive stroma. Recent studies suggest that human adipose-derived stromal cells (ASCs) may be similar to BMSCs, whereas stromal cells derived from human dermis (DSCs) have none of these properties (and serve as a negative control for most experiments in vitro and in vivo). How similar or dissimilar these different stromal cell populations are has yet to be determined. Molecular profiling is needed to compare these different populations and in order to elucidate the factors that control differentiation stromal cells into one cell type or another.

Objectives: Surgical waste (bone with red marrow, dermis, spleen, thymus and adipose tissues) from males and females of varying ages undergoing clinically indicated surgical procedures will be used to establish stromal cell cultures to study the molecular profile and differentiation capacity of the stromal cell populations from different tissues and to further characterize the regulation of gene expression and protein synthesis in these stem/progenitor cells.

Eligibility: Any patient who is undergoing clinically indicated surgery that entails removal of bone with red marrow, dermis, spleen, thymus and adipose tissue, and who do not have: 1) a history of metabolic bone disease, 2) any form of cancer or have been treated by chemotherapy or irradiation for cancer, and 3) have not received agents known to affect bone metabolism.

Design: Normal surgical waste (bone with red marrow, dermis, spleen, thymus and adipose) from procedures that are performed on males and females at Suburban Hospital will be placed in nutrient medium (provided by NIDCR) and sent to the NIDCR for the establishment of cell culture strains. Only the age, gender and site from which the tissue was removed will be recorded. The cell cultures from the different tissues will be used to determine their phenotypic character and differentiation properties by molecular profiling, and for studies to elucidate the regulation of gene expression and protein synthesis. Similarly, a portion of the samples obtained at Suburban Hospital will be used to generate histological sections of the normal tissues that will be used to screen newly developed antibodies and molecular probes. In some cases, RNA will be extracted from the tissues for RT-PCR analysis. These samples (cells, sections, mRNA) will also serve as normal controls for studies performed on samples obtained from patients with various diseases recruited to NIH under current NIH protocols (97-D-0055, 97-D-0145, 01-D-0184).

02

Conditions studied

  • Bone Regeneration
  • Fracture Healing
  • Cell Culture Techniques
  • Tissue Engineering
  • Differentiation

Keywords

  • Connective Tissue
  • Stromal Cells
  • Surgical Waste
  • In Vivo Studies
  • Tissue Analysis
03

In context

Lead sponsor

National Institute of Dental and Craniofacial Research (NIDCR) is the lead sponsor of 94 studies on the registry; 9 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Any patient over the age of 18 years who is undergoing a clinically indicated or elective surgery that entails removal of bone with red marrow,periosteum, dermis, spleen, thymus, muscle and adipose tissue.

All patients must sign a document of informed consent indicating their understanding that the specimens collected and demographic information provided is only for research purposes.

Exclusion criteria

EXCLUSION CRITERIA:

Any patient that has a history of metabolic bone disease.

Any patient that has cancer of any type, or has been treated for cancer of any type.

Any patient that has been treated with a reagent known to affect bone metabolism (bisphosphonates, steroids, vitamin D)

05

Study design

Time perspective
Prospective
Enrollment
2 participants (actual)
06

Study locations

1 site
  • Suburban Hospital
    Bethesda, Maryland 20814, United States
07

References and documents

Publications

  • Bianco P, Riminucci M, Kuznetsov S, Robey PG. Multipotential cells in the bone marrow stroma: regulation in the context of organ physiology. Crit Rev Eukaryot Gene Expr. 1999;9(2):159-73. doi: 10.1615/critreveukargeneexpr.v9.i2.30. PubMed 10445154 ↗
  • Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation. 1974 Apr;17(4):331-40. doi: 10.1097/00007890-197404000-00001. No abstract available. PubMed 4150881 ↗
  • Gronthos S, Franklin DM, Leddy HA, Robey PG, Storms RW, Gimble JM. Surface protein characterization of human adipose tissue-derived stromal cells. J Cell Physiol. 2001 Oct;189(1):54-63. doi: 10.1002/jcp.1138. PubMed 11573204 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2007
First posted
Feb 16, 2007
Start
Jan 29, 2007
Completion
Nov 5, 2012
Last update
Dec 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Dec 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00435877
First posted
Feb 16, 2007
Start date
Jan 29, 2007
Completion
Nov 5, 2012
Last update
Dec 17, 2019

Study contacts

Pamela G Robey, Ph.D.
principal investigator · National Institute of Dental and Craniofacial Research (NIDCR)
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion